Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

about

Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients.

P2860

Q33631646-D071CEBD-A35A-42E9-AE21-6DA4BEBB21FA

P2860

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

Item

http://www.wikidata.org/entity/Q40584386

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

@en

type

Item

label

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

@en

prefLabel

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

@en

P1476

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

@en

P2093

Jennifer Shelton

http://www.w3.org/2001/XMLSchema#string

Melanie Poulin-Costello

http://www.w3.org/2001/XMLSchema#string

Nabil Bayan

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor.

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.

A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.

P304

106-112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1203475415604322

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kim A. Papp

M Gooderham

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26330052

http://www.w3.org/2001/XMLSchema#string

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

about

P2860

P2860

Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698